Theravance Biopharma is cutting 50% of its workforce, roughly 200 people, after a Phase 3 clinical trial failure. The company is shutting down its R&D operations entirely, transforming from a drug development company into what amounts to a holding entity for its remaining pipeline assets.
A 50% cut is among the deepest percentage reductions of any company in 2026. When a biotech loses its lead clinical program, there is often nothing left to build on. Theravance's remaining employees will largely be focused on winding down operations or attempting to out-license the company's remaining intellectual property.